SEC Comment Letter 0000000000-24-009433 to Evoke Pharma Inc (EVOK) (CIK 0001403708)
Evoke Pharma Inc (EVOK) (CIK 0001403708)
Date: Aug. 16, 2024 · CIK: 0001403708 · Accession: 0000000000-24-009433
AI Filing Summary & Sentiment
File numbers found in text: 333-281527
Letter
August 16, 2024 Matthew D'Onofrio Chief Executive Officer Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Re:Evoke Pharma, Inc. Registration Statement on Form S-3 Filed August 13, 2024 File No. 333-281527 Dear Matthew D'Onofrio: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Anthony A. Gostanian, Esq.
Show Raw Text
August 16, 2024
Matthew D'Onofrio
Chief Executive Officer
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 230
Solana Beach, CA 92075
Re:Evoke Pharma, Inc.
Registration Statement on Form S-3
Filed August 13, 2024
File No. 333-281527
Dear Matthew D'Onofrio:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Anthony A. Gostanian, Esq.